Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Biologics Timing Depends On FDA Commissioner, Barr Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The products could be on the market within three years if an FDA commissioner of former chief McClellan's "disposition" is confirmed, CEO Downey says. The process could take longer if the confirmed commissioner is more "reticent to change."

You may also be interested in...



Crawford’s FDA Confirmation Woes Grow With Sen. Coburn’s Threatened Hold

The Oklahoma Republican says he will place a hold on FDA Commissioner nominee Crawford because the agency has not finalized condom labeling rules. Coburn joins a list of Democrats who are also threatening to place a hold on Crawford’s nomination.

Barr To Pursue Generic Version of Neupogen Under Agreement With Pliva

Barr agreement with Pliva marks the generic drug marketer's second move into generic biologics, with the company aiming to become an early leader in the field. Barr will be responsible for regulatory work to establish a pathway for approval of G-CSF.

Barr’s First Biologic Product Candidate Is Adenovirus Vaccine

The company is developing the product under a contract with the federal government, which sought a new manufacturer after Wyeth ceased production of its vaccine in 1996. Barr expects to file an application to market the product by 2007.

Related Content

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel